Literature DB >> 6383322

Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.

H U Schorlemmer, K Bosslet, G Dickneite, G Lüben, H H Sedlacek.   

Abstract

The effects of Bestatin, a low molecular weight metabolite of Streptomyces olivoreticuli on the human and mouse/rat immune system, have been studied in detail. To describe the activity of the immunomodulating dipeptide, it has been tested in vitro, ex vivo and in vivo in various experimental models. Bestatin simultaneously applied with selected antigens to mice was able to enhance the DTH response against a challenge injection of the respective antigen given into the footpad. Serum antibody levels against those antigens were uneffected. However, an increase of PFC could be found in those mice given high doses of Bestatin. On natural killer cell activity against Yac-1 tumor cells the dipeptide had no effect in low responder (DBA2/J) mice. In high responder mice (CBA/JCr), however, a significant increase of NK cell activity of spleen cells could be found, when the drug was given on day 0 or on days 0 to 3 and the test was performed on day 4. Bestatin had no effect on the generation of allogeneic cytotoxic T-lymphocytes in vivo or in vitro and even a suppressive effect on the induction of syngeneic antitumor CTL. Contrary to this suppressive effect, Bestatin increases in the popliteal lymph node assay the weights in a dose-dependent way. When mouse macrophages or human monocytes were either incubated in vitro with Bestatin or mice were treated with the dipeptide parenterally or orally and the macrophages from those mice were investigated, Bestatin induced in vitro and in vivo a dose-dependent increase in pinocytic uptake of radioactive colloidal gold. Also the oxidative metabolism was dose-dependently augmented as measured by chemiluminescence. Bestatin modulates the macrophage mediated cytotoxicity. In vitro or in vivo activated mononuclear phagocytes exhibited a dose-dependent increase in cytotoxic activity for several tumor target cells. A minimum ratio of 50:1 effector to target cells was necessary for this cytotoxic effect. A similar degree of activation was observed in macrophages from athymic nu/nu-mice or from endotoxin resistant C3H/HeJ-mice. Other parameters of macrophage activation were determined by measuring secretion of lysosomal enzymes and liberation of prostaglandins. Bestatin interacts with macrophages in vivo and in vitro by increasing their secretory activity of acid hydrolases (beta-glucuronidase, beta-galactosidase, and N-acetyl-beta-D-glucosaminidase). This release was dose- and time-dependent and not associated with any sign of cell death. Another class of mediators produced by macrophages after stimulation with Bestatin were the prostaglandins E2 and F2a.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6383322

Source DB:  PubMed          Journal:  Behring Inst Mitt        ISSN: 0301-0457


  10 in total

1.  Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases.

Authors:  F Abe; G Alvord; M Koyama; A Matsuda; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  In vivo labelling of granulocytes with 99mTc anti-NCA monoclonal antibodies for imaging inflammation.

Authors:  K Joseph; H Höffken; K Bosslet; H U Schorlemmer
Journal:  Eur J Nucl Med       Date:  1988

3.  Prolongation of graft survival in allogeneic islet transplantation by (-) 15-deoxyspergualin in the rat.

Authors:  P K Walter; G Dickneite; H U Schorlemmer; H H Sedlacek; S Jäger; G Feifel; G Seitz
Journal:  Diabetologia       Date:  1987-01       Impact factor: 10.122

4.  Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice.

Authors:  F Abe; A Matsuda; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin).

Authors:  J Yoneda; I Saiki; H Fujii; F Abe; Y Kojima; I Azuma
Journal:  Clin Exp Metastasis       Date:  1992-01       Impact factor: 5.150

6.  Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice.

Authors:  F Abe; M Schneider; P L Black; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 7.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

8.  Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.

Authors:  Douglas R Davies; Bjorn Mamat; Olafur T Magnusson; Jeff Christensen; Magnus H Haraldsson; Rama Mishra; Brian Pease; Erik Hansen; Jasbir Singh; David Zembower; Hidong Kim; Alex S Kiselyov; Alex B Burgin; Mark E Gurney; Lance J Stewart
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

Review 9.  The role of medical structural genomics in discovering new drugs for infectious diseases.

Authors:  Wesley C Van Voorhis; Wim G J Hol; Peter J Myler; Lance J Stewart
Journal:  PLoS Comput Biol       Date:  2009-10-26       Impact factor: 4.475

10.  Inhibition of tumor cell invasion by ubenimex (bestatin) in vitro.

Authors:  I Saiki; J Murata; K Watanabe; H Fujii; F Abe; I Azuma
Journal:  Jpn J Cancer Res       Date:  1989-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.